Moteur de recherche d’entreprises européennes
Financement de l’UE (150 000 €) : Antagonisation de la signalisation de la GnRH en tant que stratégie thérapeutique « holistique » pour le syndrome des ovaires polykystiques Hor25/07/2023 Programme de recherche et d'innovation de l'UE « Horizon »
Texte
Antagonisation de la signalisation de la GnRH en tant que stratégie thérapeutique « holistique » pour le syndrome des ovaires polykystiques
PCOS is the most common endocrine disorder affecting up to 18% of women worldwide. The syndrome imposes a heavy health burden, covering infertility, obesity, type 2 diabetes and metabolic syndrome. The development of treatment options is an urgent need since there is currently neither a cure nor mechanism-based treatments, leaving patient management suboptimal and focused solely on symptomatic treatment. One key neuroendocrine aberration in most women with PCOS is increased luteinizing hormone (LH) pulse frequency. This suggests an increase in activity of gonadotropin-releasing hormone (GnRH) neurons in the hypothalamus. The LH hyper-pulsatility contributes to increased ovarian thecal androgen secretion and failure of ovulation, constituting a pivotal pathogenic role in the syndrome. These evidences suggest that alterations of GnRH neuronal activity/secretion could be the basis for neuroendocrine anomalies that accompany the reproductive disturbances in the syndrome. In GRASP we will test the hypothesis that low administration doses of a GnRH antagonist, aimed at tempering LH secretion/pulsatility, can ameliorate both reproductive and metabolic PCOS traits in animal models of PCOS and in women with PCOS. The specific objectives of GRASP are to i) dose-range GnRH antagonism to rectify LH pulse amplitude and frequency in PCOS-like mice ; ii) to perform a long-term treatment with the selected doses of GnRH antagonist to assess its potential beneficial outcomes in correcting reproductive and metabolic alterations of this preclinical model; iii) to perform a pilot dose-effect clinical investigation testing the ability of sub-therapeutic doses of GnRH antagonist to rectify the altered hormonal dynamics in women with PCOS. The overall goal of GRASP is to provide a proof-of-concept for future long-duration randomized controlled trials of this approach to appraise its clinical benefits in women with PCOS and to move forward towards therapeutic innovation.
| Centre Hospitalier Regional et Universitaire de Lille | 0,00 € |
| Institut National de la Sante et de la Recherche Medicale | 150 000 € |
https://cordis.europa.eu/project/id/101111874
Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel.